Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
J Med Microbiol ; 71(5)2022 May.
Article in English | MEDLINE | ID: mdl-35580018

ABSTRACT

Introduction. Two high-oncogenic-risk human papilomavirus (hrHPV) genotypes - HPV16 and HPV18 - cause most of the cases of cervical cancer worldwide. Bacterial vaginosis is associated with increased hrHPV persistence, although the mechanism underlying this association remains unclear. Gardnerella spp. are detected in nearly all cases of bacterial vaginosis and are the major source of cervicovaginal sialidases. The NanH1 gene is present in virtually all Gardnerella sialidase-producing strains and has been proposed as a potential marker for persistent hrHPV infection.Hypothesis. Gardnerella spp. load and the NanH1 gene are associated with hrHPV persistence.Aim. To compare the cervicovaginal load of Gardnerella spp. and the frequency of the NanH1 gene between women with persistent HPV16 and/or HPV18 infection and those who cleared the infection after 11 months.Methodology. Among a population of 1638 HPV screened, we detected 104 with positive HPV16 and/or HPV18 results. Samples were obtained at two time points (baseline and at a median of 11 months at follow-up) and tested using the Linear Array HPV Genotyping kit (Roche Molecular Systems, Pleasanton, CA, USA). Based on their HPV16/HPV18 status at enrolment and follow-up, participants were assigned to 'persistence' or 'clearance' groups. We used cervicovaginal fluid samples obtained upon enrolment to determine the load of the 23 s rRNA gene of Gardnerella spp. and the presence of the NanH1 gene using real-time polymerase chain reaction (PCR). We compared Gardnerella spp. loads and NanH1 frequency between the groups by, respectively, Mann-Whitney and chi-squared tests, with a P-value <0.05 considered to be significant.Results. Of the 104 participants who were positive for HPV16/HPV18, 73 (70.2 %) persisted with at least 1 of the baseline genotypes at follow-up, while 31 (29.8 %) cleared the infection in this time frame. Participants in the persistence group had significantly higher loads of Gardnerella spp. [5.8E+02 (0-3.0E+05) copies µl-1] than those in the clearance group [9.9E+01 (0-7.7E+04) copies µl-1] (P=0.03). The baseline frequency of NanH1 was higher in the persistence' (n=46, 63.0 %) than in the clearance (n=14, 45.2 %) group, although this was not statistically significant (P=0.09).Conclusion. These findings reinforce the negative effect of vaginal microbiota for the clearance of hrHPV and indicate a possible association between sialidase-producing species with hrHPV persistence.


Subject(s)
Papillomavirus Infections , Uterine Cervical Neoplasms , Vaginosis, Bacterial , Female , Gardnerella/genetics , Human papillomavirus 16/genetics , Human papillomavirus 18/genetics , Humans , Neuraminidase
2.
Braz Oral Res ; 33: e031, 2019.
Article in English | MEDLINE | ID: mdl-30994708

ABSTRACT

Variable rates of HPV infection have been reported in healthy oral mucosa worldwide. The main objective of this study was to detect and genotype HPV infection in users and nonusers of drugs with clinically healthy mucosa from the Northeast Brazil. Samples from 105 patients were amplified using the primers MY09/MY11 and GP5+/GP6+, and genotyping was performed by multiplex-PCR for HPV-6/11, 16 and 18. A total of 81.9% samples were positive. Among drug users, 84.5% presented the virus and 20.4% showed multiple infections. Among non-drug users, 78.7% were positive and 13.5% had multiple infections. Limited information is available on oral HPV in Brazilian population, especially for drug users, and our results showed higher HPV infection rates in both users and nonusers of drugs. More studies and researches focused on drug users including factors like sexual behavior, nutrition and cultural habits are necessary to enhance the comprehension of this relationship, and develop preventive strategies.


Subject(s)
Mouth Mucosa/virology , Papillomavirus Infections/epidemiology , Papillomavirus Infections/etiology , Substance-Related Disorders/complications , Substance-Related Disorders/virology , Adolescent , Adult , Age Distribution , Brazil/epidemiology , Case-Control Studies , Cross-Sectional Studies , DNA, Viral , Female , Humans , Male , Middle Aged , Papillomaviridae/isolation & purification , Polymerase Chain Reaction , Prevalence , Prospective Studies , Risk Assessment , Risk Factors , Risk-Taking , Sex Distribution , Sexual Behavior , Socioeconomic Factors , Young Adult
3.
J Low Genit Tract Dis ; 21(3): 189-192, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28430679

ABSTRACT

OBJECTIVE: This study included women attending primary health care units in Botucatu, São Paulo, Brazil, to assess the cervicovaginal levels of human ß-defensin (hBD) 1, 2, 3, and 4 during Chlamydia trachomatis infection. PATIENTS AND METHODS: Cervicovaginal samples were collected for Pap testing and assessing the presence of infection by C. trachomatis, human papillomavirus, Neisseria gonorrhoeae, and Trichomonas vaginalis. Vaginal smears were taken to evaluate local microbiota. Human ß-defensin levels were determined using enzyme-linked immunosorbent assay in cervicovaginal fluid samples. Seventy-four women with normal vaginal microbiota and no evidence of infection were included in hBD quantification assays; 37 tested positive for C. trachomatis and 37 were negative. Statistical analysis was performed using Mann-Whitney U test. RESULTS: Women positive for C. trachomatis had significantly lower cervicovaginal hBD-1, hBD-2, and hBD-3 compared with those who tested negative (hBD-1: 0 pg/mL [0-2.1] vs 1.6 pg/mL [0-2.4], p < .0001; hBD-2: 0 pg/mL [0-3.9] vs 0.61 pg/mL [0-8.9], p = .0097; and hBD-3: 0 pg/mL [0-4.3] vs 0.28 pg/mL [0-8.4], p = .0076). Human ß-defensin 4 was not detected. CONCLUSIONS: Lower levels of hBD-1, hBD-2, and hBD-3 in cervicovaginal fluid were detected in the presence of C. trachomatis infection.


Subject(s)
Cervix Uteri/pathology , Chlamydia Infections/pathology , Chlamydia trachomatis/isolation & purification , Vagina/pathology , beta-Defensins/analysis , Adolescent , Adult , Brazil , Enzyme-Linked Immunosorbent Assay , Female , Humans , Middle Aged , Young Adult
4.
J Appl Oral Sci ; 25(1): 69-74, 2017.
Article in English | MEDLINE | ID: mdl-28198978

ABSTRACT

OBJECTIVE: The aim of this study was to evaluate the frequency of HPV infection and its genotypes in patients with oral lesions at the Ambulatory of Oral Diagnosis of the Federal University of Sergipe, Brazil. MATERIAL AND METHODS: We conducted a molecular study with 21 patients (15 females) aged from two to 83 years with clinically detectable oral lesions. Samples were collected through exfoliation of lesions and HPV-DNA was identified using MY09/11 and GP5+/6+ primers. Genotyping was performed by multiplex PCR. RESULTS: Benign, premalignant and malignant lesions were diagnosed by histopathology. HPV was detected in 17 samples. Of these, HPV-6 was detected in 10 samples, HPV-18 in four and HPV-16 in one sample. When samples were categorized by lesion types, HPV was detected in two papilloma cases (2/3), five carcinomas (5/6), one hyperplasia (1/1) and nine dysplasia cases (9/11). CONCLUSION: Unlike other studies in the literature, we reported high occurrence of HPV in oral lesions. Further studies are required to enhance the comprehension of natural history of oral lesions.


Subject(s)
Mouth Diseases/epidemiology , Mouth Diseases/virology , Mouth Mucosa/virology , Papillomaviridae/isolation & purification , Papillomavirus Infections/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Base Sequence , Biopsy , Brazil/epidemiology , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/virology , Child , Child, Preschool , DNA, Viral , Female , Humans , Male , Middle Aged , Mouth Diseases/pathology , Mouth Mucosa/pathology , Multiplex Polymerase Chain Reaction , Papillomaviridae/genetics , Papillomavirus Infections/genetics , Prevalence , Risk Assessment , Time Factors , Young Adult
5.
J. appl. oral sci ; 25(1): 69-74, Jan.-Feb. 2017. tab, graf
Article in English | LILACS, BBO - Dentistry | ID: biblio-841168

ABSTRACT

Abstract The role of human papillomavirus (HPV) in oral carcinogenesis is still controversial as detection rates of the virus in oral cavity reported in the literature varies greatly. Objective The aim of this study was to evaluate the frequency of HPV infection and its genotypes in patients with oral lesions at the Ambulatory of Oral Diagnosis of the Federal University of Sergipe, Brazil. Material and Methods We conducted a molecular study with 21 patients (15 females) aged from two to 83 years with clinically detectable oral lesions. Samples were collected through exfoliation of lesions and HPV-DNA was identified using MY09/11 and GP5+/6+ primers. Genotyping was performed by multiplex PCR. Results Benign, premalignant and malignant lesions were diagnosed by histopathology. HPV was detected in 17 samples. Of these, HPV-6 was detected in 10 samples, HPV-18 in four and HPV-16 in one sample. When samples were categorized by lesion types, HPV was detected in two papilloma cases (2/3), five carcinomas (5/6), one hyperplasia (1/1) and nine dysplasia cases (9/11). Conclusion Unlike other studies in the literature, we reported high occurrence of HPV in oral lesions. Further studies are required to enhance the comprehension of natural history of oral lesions.


Subject(s)
Humans , Male , Female , Child, Preschool , Child , Adolescent , Adult , Middle Aged , Aged , Aged, 80 and over , Young Adult , Papillomaviridae/isolation & purification , Papillomavirus Infections/epidemiology , Mouth Diseases/epidemiology , Mouth Diseases/virology , Mouth Mucosa/virology , Papillomaviridae/genetics , Time Factors , Biopsy , Brazil/epidemiology , DNA, Viral , Base Sequence , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/virology , Prevalence , Risk Assessment , Papillomavirus Infections/genetics , Multiplex Polymerase Chain Reaction , Mouth Diseases/pathology , Mouth Mucosa/pathology
6.
Clin Rev Allergy Immunol ; 52(3): 373-388, 2017 Jun.
Article in English | MEDLINE | ID: mdl-27484684

ABSTRACT

Vitamin D (VitD) is a hormone primarily synthesized in human skin under the stimulation of ultraviolet radiation. Beyond its endocrine role in bone metabolism, VitD is endowed with remarkable immunomodulatory properties. The effects of VitD on the immune system include the enhancement of microbicidal ability of monocytes/macrophages and the down-modulation of inflammatory cytokines produced by T lymphocytes. VitD deficiency is involved in many health problems, including immune-mediated diseases such as autoimmune disorders. Rheumatoid arthritis (RA) is a chronic inflammatory systemic autoimmune disease that compromises the joints, causing cartilage destruction and bone erosion. RA treatment usually consists of combined therapies that generally suppress the entire immune response leading to increased susceptibility to infections. This review describes the main effects of VitD on innate and adaptive immune system and also VitD status in inflammatory rheumatic diseases such as RA. Despite some controversies, the majority of reports reinforce the idea that lower VitD levels correlate with more severe clinical manifestations in RA and other rheumatic diseases. Therefore, supplementation with VitD to achieve normal serum levels is worthwhile as an aforethought. Original data concerning the potential applicability of 1,25-dihydroxyvitamin D3 (VitD3), the active form of vitamin D, as a tolerogenic adjuvant are also included. In this sense, the effect of VitD3 associated with proteoglycan (PG), which is a specific cartilage antigen, was tested in the course of experimental arthritis. This association significantly lowered clinical scores and local histopathological alterations. Even though local analysis of T cell subsets and cytokine production did not reveal any difference between the experimental groups, VitD3+PG association significantly reduced cytokine production by spleen cells. These results suggest that VitD3 played a role as a tolerogenic adjuvant by down-modulating the course of experimental RA. Considering this tolerogenic effect of VitD3+PG association, further investigations will reveal its plausible use in human RA.


Subject(s)
Anti-Inflammatory Agents/metabolism , Arthritis, Experimental/immunology , Arthritis, Rheumatoid/immunology , Vitamin D Deficiency/immunology , Vitamin D/metabolism , Adaptive Immunity , Animals , Arthritis, Experimental/therapy , Arthritis, Rheumatoid/therapy , Autoimmunity , Cartilage/drug effects , Cartilage/pathology , Humans , Immune Tolerance , Immunity, Innate , Immunomodulation , Inflammation , Proteoglycans/metabolism , Vitamin D/therapeutic use , Vitamin D Deficiency/therapy
7.
J Immunol Res ; 2016: 6765134, 2016.
Article in English | MEDLINE | ID: mdl-27294161

ABSTRACT

This study was undertaken to evaluate the prophylactic potential of proteoglycan (PG) administration in experimental arthritis. Female BALB/c retired breeder mice received two (2xPG50 and 2xPG100 groups) or three (3xPG50 group) intraperitoneal doses of bovine PG (50 µg or 100 µg) every three days. A week later the animals were submitted to arthritis induction by immunization with three i.p. doses of bovine PG associated with dimethyldioctadecylammonium bromide adjuvant at intervals of 21 days. Disease severity was daily assessed after the third dose by score evaluation. The 3xPG50 group showed significant reduction in prevalence and clinical scores. This protective effect was associated with lower production of IFN-γ and IL-17 and increased production of IL-5 and IL-10 by spleen cells restimulated in vitro with PG. Even though previous PG administration restrained dendritic cells maturation this procedure did not alter the frequency of regulatory Foxp3(+) T cells. Lower TNF-α and IL-6 levels and higher expression of ROR-γ and GATA-3 were detected in the paws of protected animals. A delayed-type hypersensitivity reaction confirmed specific tolerance induction. Taken together, these results indicate that previous PG inoculation determines a specific tolerogenic effect that is able to decrease severity of subsequently induced arthritis.


Subject(s)
Arthritis, Experimental/etiology , Arthritis, Experimental/prevention & control , Protective Agents/administration & dosage , Proteoglycans/administration & dosage , Animals , Arthritis, Experimental/pathology , Cell Differentiation , Cytokines/metabolism , Dendritic Cells/cytology , Dendritic Cells/immunology , Dendritic Cells/metabolism , Disease Models, Animal , Female , Mice , Mice, Inbred BALB C , Severity of Illness Index , T-Lymphocytes, Regulatory/immunology , T-Lymphocytes, Regulatory/metabolism , Transcription Factors/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...